A
Alcista
Alcista · 25%BLRX
$4.97
Precio del escenario
$1.730
-0.037 (-2.15%)Al cierre
Loading chart…
- Máximo
- 1.750
- Apertura
- 1.715
- Precio medio ponderado por volumen
- 1.73
- Volumen
- 7.76K
- Capitalización
- 45.57M
- Mínimo
- 1.709
- Importe
- 13.42K
- EV/EBITDA, TTM
- -0.45
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Análisis de IA of BioLine RX Ltd (BLRX)
VenderBioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.
Recomendaciones de analistas (4)
+593.64% de potencial alcista
Comprar
4 Comprar
0 Mantener
0 Vender
Actual: 1.73
Mínimo
12.00
Promedio
12.00
Máximo
12.00
Jones Trading
Mantener
—
2025-04-02
Jones Trading
2025-04-02
Precio objetivo
—
Mantener
HC Wainwright & Co.
Compra fuerte
$26
2025-03-31
HC Wainwright & Co.
2025-03-31
Precio objetivo
$26
Compra fuerte
HC Wainwright & Co.
Compra fuerte
$9
2024-11-25
HC Wainwright & Co.
2024-11-25
Precio objetivo
$9
Compra fuerte
HC Wainwright & Co.
Compra fuerte
$21
2024-11-06
HC Wainwright & Co.
2024-11-06
Precio objetivo
$21
Compra fuerte
Jones Trading
Compra fuerte
$2
2024-09-04
Jones Trading
2024-09-04
Precio objetivo
$2
Compra fuerte
Métricas de valoración
El PER previsto actual de BioLine RX Ltd (BLRX) es 93.46, frente a su media de 5 años de 15.21.
Escenarios de precio de Alphio AI para BLRX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.010-23PRnewswireGLIX1 Shows Significant Synergy with PARP Inhibitors
8.510-08PRnewswireBioLineRx and Hemispherian to Present GLIX1 at SNO Annual Meeting
5.009-01NASDAQ.COMLifeward Appoints New CEO and CFO Amid Leadership Transition
9.508-31Yahoo FinanceBioLineRx Reports Q2 2026 Earnings with Increased R&D Expenses
8.508-31PRnewswireBioLineRx Reports Significant Progress in GLIX1 Clinical Trials
Preguntas frecuentes sobre BLRX, respondidas por Alphio AI
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment. It operates in the Healthcare sector.
BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.
4 analysts cover BLRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.